Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 6

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 6
---
’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.

As
of November 1, 2022, our reporting currency and functional currency is the United States Dollar. Prior to that, our reporting currency
and functional currency was the Canadian Dollar. Unless otherwise expressly stated or the context otherwise requires, references in this
prospectus to “CAD$” are to Canadian Dollars. Amounts denominated in United States Dollars are states as “$” “dollars”
or “USD”. Where previously disclosed financial information was in Canadian Dollars, we have included a convenience translation.

This
prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally
state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness
of the information.

We
report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB. None
of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.

On September 30, 2022, we
effected a one-for-30 consolidation of our issued and outstanding common shares. In addition, on November 28, 2023, we effected a one-for-30
consolidation of our issued and outstanding common shares. Except where otherwise indicated, all share and per share data in this prospectus
supplement have been retroactively restated to reflect the aforementioned consolidations.

<div align='center'>ii

PROSPECTUS SUMMARY</div>

This summary highlights information contained elsewhere in or incorporated by reference into this prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and related notes incorporated by reference into this prospectus and the other documents incorporated by reference into this prospectus, which are described under “Incorporation by Reference” before making an investment in our securities.

Company Overview

We are a clinical pharmaceutical
company currently engaged in phase I/IIa clinical trials of novel psychedelic medicines to solve widespread, yet under-served, health
problems. Our goal is to develop and provide new type of